Interim results were presented at the American Academy of Ophthalmology (AAO) meeting in New Orleans USA, November 11-14 2017.

LIGHTSITE I enrolled 30 dry AMD subjects who were randomized (1:1) to PBM treatment or sham treatment.

“We have examined the interim data from the LIGHTSITE I study for up to the first 3 months following treatment with a multi-wavelength PBM therapy and results have demonstrated statistically significant vision benefits in dry AMD patients that were maintained for the 3 month interval,” stated Samuel Markowitz, M.D., Co-Principal Investigator, Department of Ophthalmology and Vision Sciences, University of Toronto. “The PBM treatment was most beneficial in AMD patients with better vision reaching statistically significant benefits in both visual acuity and contrast sensitivity (p < 0.05).”

Dr. Robert Devenyi, Co-Principal Investigator, Ophthalmologist in Chief and Director of Retinal services, University Health Network, University of Toronto has stated: “The results show PBM using the LT-300 device can improve vision for dry AMD patients and could be an important option for these patients to counteract the degradation in vision that this disabling disease brings.”

“The positive interim data from this prospective, sham controlled, double-masked pilot clinical dry AMD study further substantiates PBM therapy as a safe non invasive treatment for dry AMD patients” states Dr. Graham Merry, Co Author of the paper.